Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW2821 vs Chemotherapy in Advanced Triple-Negative Breast Cancer
NCT07556848Phase 3Not yet recruiting
- Sponsor
- Mabwell
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bulumtatug fuvedotin in triple-negative breast cancer (TNBC) (2 arms), sponsored by Mabwell. Primary endpoint: Overall Survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07556848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556848.